At the State University of Campinas in Brazil, researchers have found that the body itself carries a story about cancer's trajectory — one that tumor staging alone cannot tell. By combining measurements of fat and muscle density from routine CT scans into a single marker called VMD, the team revealed a fourfold difference in median survival between high- and low-risk gastric cancer patients. The work reflects a deepening conviction in oncology that the terrain in which a disease grows matters as much as the disease itself, and that precision medicine may already be visible in images we already
News-Medical
· Jun 17, 2026
· health
· 5 min read
High
Sourcing: Verified
Brazilian researchers develop CT-based biomarker to predict gastric cancer prognosis
Gastric cancer patients with unfavorable VMD markers face significantly reduced survival outcomes, with median survival of 13.8 months compared to 58.5 months for better-risk patients.
◉
Health & Medicine
8046 related articles
Blood test could predict Covid-19 mortality risk, study finds
BreakingNews.ie · 100% match
Hadassah performs world's first alpha radiation treatment for recurren…
jpost.com · 99% match
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge…
NDTV Profit · 99% match
EU safety committee reviews reports of menstrual changes after mRNA CO…
CNBC · 99% match
Canada faces new COVID epidemic, not third wave, as variants target di…
The Globe and Mail · 99% match
Related Coverage
Google News · Aug 19
Welsh Teen's Ovarian Cancer Diagnosis Triggers Sudden Menopause
A teenager from Caernarfon experienced sudden onset menopause following an ovarian cancer diagnosis, highlighting unexpe…
JNS.org · Aug 19 Israeli study: Focused attention may reduce inflammatory responseBar-Ilan University researchers found that deliberately focusing attention on inflamed skin areas reduced inflammatory r…
foodsafetynews.com · Aug 19 UK Salmonella outbreak sickens 207, linked to imported eggsA Salmonella outbreak across the UK has infected 207 people with one death, traced to contaminated imported eggs served …
eNCA · Aug 19 DRC Ebola outbreak spreading faster than any previous epidemic, WHO warnsWHO warns the DRC Ebola outbreak is moving faster than any previous epidemic, with over 2,300 deaths from nearly 5,000 c…
Bias & Framing
⚖
Article presents medical research findings with straightforward reporting; minimal bias detected, though lacks critical perspective on study limitations and generalizability.
Bias Direction
center
Confidence
MED
Positive innovation framing emphasizing breakthrough potential without substantial critical examination or limitations discussion
may help determine
pave the way for
more personalized treatment approach
shift in perspective
look at the patient as a whole
Study limitations and sample size details
Comparison with competing biomarkers or alternative approaches
Cost-effectiveness analysis or clinical implementation challenges
Skeptical expert commentary from independent researchers
Timeline for clinical adoption and regulatory approval
Potential limitations of CT-based assessment
Geopolitical Impact
🌎
Brazilian medical research advances gastric cancer prognosis prediction through a new CT-based biomarker, with potential global healthcare applications but limited geopolitical significance.
Escalation Risk
low
Confidence
HIGH
This is primarily a medical/scientific development with no direct geopolitical implications. Brazil demonstrates research capability in oncology, potentially enhancing its soft power in healthcare innovation.
Economic Lens
📈
Brazilian researchers developed VMD biomarker combining visceral fat and muscle density from CT scans to predict gastric cancer prognosis, enabling personalized treatment and potentially reducing unnecessary interventions.
Market Signal
bullish
Confidence
MED
Healthcare/Oncology
Medical Diagnostics
Pharmaceutical/Treatment Development
Medical Imaging Technology
Health Insurance
Patients with gastric cancer could receive more personalized treatment plans based on individual prognosis, potentially improving outcomes, reducing adverse effects from unnecessary aggressive treatments, and lowering overall healthcare costs through targeted therapy approaches.
Healthcare systems may need to update diagnostic protocols and reimbursement models to incorporate body composition analysis alongside traditional tumor staging. Regulatory bodies may require validation studies before widespread clinical adoption. Insurance coverage policies may shift to incentivize personalized medicine approaches.